Somewhat Positive Media Coverage Somewhat Unlikely to Impact Intercept Pharmaceuticals (ICPT) Stock Price
News headlines about Intercept Pharmaceuticals (NASDAQ:ICPT) have trended somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a news impact score of 0.11 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.9677064010628 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media headlines that may have effected Accern’s analysis:
- -$3.40 Earnings Per Share Expected for Intercept Pharmaceuticals, Inc. (ICPT) This Quarter (americanbankingnews.com)
- Intercept Pharmaceuticals (ICPT) Lowered to Sell at BidaskClub (americanbankingnews.com)
- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Notable Indicators to Study Before Making Any Investment Decision – Nasdaq Journal (press release) (nasdaqjournal.com)
- Hot Stock Analysis – Intercept Pharmaceuticals, Inc., (NASDAQ: ICPT) – Stock Watch (stocksnewstimes.com)
- Intercept to Present at Upcoming Conference (markets.financialcontent.com)
A number of research analysts recently weighed in on ICPT shares. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 24th. Wedbush restated an “outperform” rating and issued a $253.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, August 25th. ValuEngine upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Wells Fargo & Company restated an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Finally, Cantor Fitzgerald restated an “underweight” rating and issued a $69.00 price target on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $144.13.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $61.34 on Tuesday. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals has a 1 year low of $54.98 and a 1 year high of $135.59.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.48) by $0.59. The firm had revenue of $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company’s revenue was up 697.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($3.59) EPS. analysts predict that Intercept Pharmaceuticals will post -13.35 earnings per share for the current fiscal year.
In other news, CEO Mark Pruzanski sold 1,532 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total transaction of $90,188.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 2,566 shares of company stock valued at $151,025. Corporate insiders own 4.50% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.